Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Single and multifraction SBRT found comparable for lung metastases

Publish date:: October 28, 2020

Key clinical point: Single-fraction stereotactic body radiotherapy may offer a safe, efficacious alternative to multifraction SBRT for treating lung oligometastases.

Major finding: The single-fraction regimen and the multifraction regimen yielded similar rates of grade 3 or worse toxicity within a year (5% and 3%, respectively) and similar rates of freedom from local failure (93% and 95%, respectively).

Study details: A phase 2, randomized trial of two SBRT regimens (28 Gy in one fraction vs. 48 Gy in four fractions) in 90 patients with one to three metastases in the lung from nonhematologic malignancies.

Disclosures: The trial is sponsored by the Trans-Tasman Radiation Oncology Group and the Australasian Lung Cancer Trials Group. Dr. Siva disclosed relationships with Varian Industries, Merck, AstraZeneca, Bayer Pharmaceuticals, Bristol-Meyers Squibb, and Reflexion.

Citation:

Siva S et al. ASTRO 2020, Abstract 5.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,